sb 203580 has been researched along with Lymphoma, Non-Hodgkin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawakami, Y; Ohkusu-Tsukada, K; Takahashi, K; Toda, M; Udono, H | 1 |
1 other study(ies) available for sb 203580 and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Animals; Clonal Anergy; Forkhead Transcription Factors; Imidazoles; Immunotherapy; Immunotherapy, Adoptive; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred Strains; Mice, Transgenic; Minor Lymphocyte Stimulatory Antigens; Molecular Sequence Data; Neoplasm Proteins; Ovalbumin; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Pyridines; Receptors, Antigen, T-Cell, alpha-beta; Superantigens; T-Lymphocytes, Regulatory; Toll-Like Receptor 9; Tumor Escape | 2010 |